Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until January 12, 2024
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until January 12, 2024
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that its 2023 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum. The Annual Meeting has been adjourned to 9:00 AM local time on January 12, 2024 at the Company's offices located at 983 University Avenue, Bldg. B, Los Gatos, CA 95032, to allow additional time for stockholders to vote on the proposals set forth in Aridis's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on November 3, 3023.
加利福尼亞州洛斯加託斯，2023年12月15日（GLOBE NEWSWIRE）——專注於發現和開發用於治療危及生命的感染的新型抗感染療法的生物製藥公司Aridis Pharmicals, Inc.（場外交易QB：ARDS）今天宣佈，定於2023年12月15日星期五舉行的2023年年度股東大會（“年會”）已召開並休會，但沒有結束由於缺乏必要的法定人數而正在開展的任何業務。年會已延期至當地時間2024年1月12日上午9點，地點位於加利福尼亞州洛斯加託斯大學大道983號B棟的公司辦公室，目的是讓股東有更多時間對Aridis於3023年11月3日向美國證券交易委員會提交的附表14A最終委託書中提出的提案進行投票。
The record date for the Annual Meeting remains November 2, 2023. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Company stockholders as of the November 2, 2023 record date can vote, even if they have subsequently sold their shares. The Company's board of directors and management respectfully request all such holders as of the record date to please vote your proxies as soon as possible.
年會的記錄日期仍然是2023年11月2日。先前已提交代理書或以其他方式投票但不想更改投票的股東無需採取任何行動。截至2023年11月2日的公司股東可以投票，即使他們隨後出售了股票。公司董事會和管理層恭敬地要求截至記錄日期的所有此類持有人儘快對您的代理人進行投票。
No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. The Company strongly advises all of its stockholders to read the proxy statement and other proxy materials relating to the Annual Meeting because they contain important information. Such proxy materials are available at no charge on the Securities and Exchange Commission's website at www.sec.gov. In addition, copies of the Proxy Statement and other documents may be obtained free of charge by accessing or by contacting the Company's Corporate Secretary at 408-385-1742 or by mail to Corporate Secretary, Aridis Pharmaceuticals, Inc., 983 University Avenue, Bldg. B, Los Gatos, CA 95032.
將由股東在年會上表決的提案沒有做出任何修改。公司強烈建議其所有股東閱讀委託書和其他與年會有關的代理材料，因爲它們包含重要信息。此類代理材料可在美國證券交易委員會的網站上免費獲得，網址爲www.sec.gov。此外，委託書和其他文件的副本可以通過訪問或聯繫公司秘書（電話408-385-1742）或郵寄給位於加利福尼亞州洛斯加託斯大學大道983號B座95032的Aridis Pharmicals, Inc.公司秘書免費獲得。
About Aridis Pharmaceuticals, Inc.
關於 Aridis 製藥有限公司
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as first-line treatments to combat antimicrobial resistance (AMR) and viral pandemics. The Company is utilizing its proprietary ʎPEX TM and MabIgX technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture mAbs for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized by the natural human immune system for high potency. Hence, they are already fit-for-purpose and do not require further engineering optimization to achieve full functionality.
Aridis Pharmicals, Inc. 發現並開發抗感染藥物，用作對抗抗微生物藥物耐藥性（AMR）和病毒流行的一線療法。該公司正在利用其專有的Pex TM和MabiGX技術平台，從成功克服感染的患者身上快速鑑定出稀有、有效的產生抗體的B細胞，並快速製造用於治療危重感染的單克隆抗體。這些單克隆抗體已經來自人類，並經過天然人類免疫系統的功能優化，具有很高的效力。因此，它們已經適合用途，不需要進一步的工程優化即可實現全部功能。
The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antibacterial and antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care, which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company's pipeline is highlighted below:
除了臨床前階段的抗菌和抗病毒單克隆抗體外，該公司還開發了多種針對導致危及生命的感染的細菌的臨床階段單克隆抗體，例如呼吸機相關性肺炎（VAP）和醫院獲得性肺炎（HAP）。使用單克隆抗體作爲抗感染治療是一種創新的治療方法，它利用人體免疫系統對抗感染，旨在克服與當前護理標準（即廣譜抗生素）相關的缺陷。這些缺陷包括但不限於耐藥性增加、療效持續時間短、人體微生物組正常菌群受到破壞以及當前治療方法之間缺乏區別。單克隆抗體產品組合輔以一種非抗生素新機制小分子抗感染候選藥物，用於治療囊性纖維化患者的肺部感染。該公司的產品線如下所示：
Aridis' Pipeline
阿里迪斯的管道
AR-301 (VAP). AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive S. aureus alpha-toxin in VAP patients.
AR-301（VAP）。AR-301 是一種全人類 IgG1 單克隆抗體，目前正處於 VAP 患者的革蘭氏陽性金黃色葡萄球菌 α-毒素的 3 期臨床開發中。
AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients. This program is currently in a Phase 2a clinical study in CF patients.
AR-501（囊性纖維化）。AR-501 是一種吸入式檸檬酸鎵配方，具有廣譜抗感染活性，用於治療囊性纖維化患者的慢性肺部感染。該項目目前正在對CF患者進行2a期臨床研究。
AR-320 (VAP). AR-320 is a fully human mAb targeting S. aureus alpha-toxin for prevention of VAP. Statistically significant Phase 2 data in the target population of those ≤ 65 years of age was published in the September 2021 Lancet Infectious Diseases journal.
AR-320 (VAP)。AR-320 是一種針對金黃色葡萄球菌 α-毒素的全人單克隆抗體，用於預防 VAP。2021 年 9 月的《柳葉刀傳染病》雜誌發佈了年齡小於 65 歲目標人群的具有統計學意義的 2 期數據。
AR-701 (COVID-19). AR-701 is a cocktail of fully human mAbs discovered from convalescent COVID-19 patients that target multiple sites on the spike proteins of the SARS-CoV-2 virus.
AR-701 (COVID-19)。AR-701 是從恢復期 COVID-19 患者身上發現的全人單克隆抗體的混合物，靶向 SARS-CoV-2 病毒刺突蛋白上的多個位點。
AR-101 (HAP). AR-101 is a fully human IgM mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa liposaccharides serotype O11, which accounts for approximately 22% of all P. aeruginosa hospital acquired pneumonia cases worldwide. This program is licensed to the Serum Institute of India and Shenzhen Arimab.
AR-101（哈哈）。AR-101 是一種全人類 IgM 單抗體，正處於 O11 型銅綠假單胞菌脂質糖血清型，約佔全球銅綠假單胞菌醫院獲得性肺炎病例總數的 22%。該項目已獲得印度血清研究所和深圳Arimab的許可。
AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb directed against the F-protein of diverse clinical isolates of respiratory syncytial virus (RSV). This program is licensed exclusively to the Serum Institute of India.
AR-201（呼吸道合胞病毒感染）。AR-201 是一種全人類 IgG1 單抗體，針對呼吸道合胞病毒 (RSV) 多種臨床分離株的 F 蛋白。該項目僅獲得印度血清研究所的許可。
AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative Acinetobacter baumannii.
AR-401（血液感染）。AR-401 是一項全人單克隆抗臨床前項目，旨在治療革蘭氏陰性鮑曼不動桿菌引起的感染。
譯文內容由第三人軟體翻譯。
